Evidence map›Paper›PMID 35053589›Full record

ArticleCancers2022

Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers.

Giuliana Beneduce, Antonia De Matteo, Pio Stellato, Anna M Testi, Nicoletta Bertorello, Antonella Colombini, Maria C Putti, Carmelo Rizzari, Simone Cesaro, Monica Cellini and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Giuliana BeneduceDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.
Antonia De MatteoDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.ORCID 0000-0002-9583-685X
Pio StellatoDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.ORCID 0000-0002-7400-4878
Anna M TestiDivision of Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, 00161 Rome, Italy.
Nicoletta BertorelloStem Cell Transplantation and Cell Therapy Division, Department of Pediatric Onco-Hematology, A.O.U. Città della Salute e della Scienza-Regina Margherita Children's Hospital, 10126 Turin, Italy.
Antonella ColombiniPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation c/o ASST Monza, 20900 Milan, Italy.
Maria C PuttiDepartment of Woman and Child Health, Clinic of Pediatric Haematology-Oncology, University of Padova, 35128 Padova, Italy.
Carmelo RizzariPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation c/o ASST Monza, 20900 Milan, Italy.ORCID 0000-0002-4828-3893
Simone CesaroPediatric Hematology Oncology Unit, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.ORCID 0000-0002-8698-9547
Monica CelliniPediatric Hematology Oncology Unit, Department of Mother and Child, Azienda Ospedaliero Universitaria Policlinico di Modena, 41125 Modena, Italy.
Elena BarisoneStem Cell Transplantation and Cell Therapy Division, Department of Pediatric Onco-Hematology, A.O.U. Città della Salute e della Scienza-Regina Margherita Children's Hospital, 10126 Turin, Italy.
Fara PetruzzielloDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.
Giuseppe MennaDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.
Rosanna ParasoleDepartment of Pediatric Hemato-Oncology, AORN Santobono-Pausilipon, Hospital, 80123 Naples, Italy.ORCID 0000-0003-3350-5286
Santobono Children's Hospital · ITUniversity of Milano-Bicocca · ITAzienda Ospedaliera Universitaria Integrata Verona · ITAzienda Ospedaliero-Universitaria di Modena · ITSapienza University of Rome · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Five-year event-free survival in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) currently exceeds 80-85%. However, 15-20% of patients still experience a relapsed/refractory disease. From 1 January 2015 to 31 December 2020, thirty-nine patients, 0-21 years old with r/r BCP-ALL were treated with blinatumomab with the aim of inducing remission (

Indexed as

acute lymphoblastic leukemiapediatricreal-life experiencerelapsetargeted therapytoxicity

Identifiers

PMID35053589
PMCPMC8773489
OpenAlexW4205665094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.